UNSPSC 51101693: Toltrazuril

This classification denotes an antiprotozoal agent with the molecular formula C18H14F3N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QVZ3IAR3JS, chemically known as 1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1-methyl-3-(3-methyl-4-(4-((trifluoromethyl)thio)phenoxy)phenyl)- but generally known as toltrazuril, which bears US NIH Compound Identifier 68591. European Medicines Agency schedules Toltrazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11181MIG.

UNSPSC 51101693 Toltrazuril, a Commodity code, does not reflect the work actually being solicited under this classification in recent state and local procurement activity. The code nominally identifies a specific veterinary antiprotozoal pharmaceutical, yet the recent opportunities tagged to it involve human-use pharmaceuticals, medical supplies, and pharmacy benefit program infrastructure—categories that fall outside toltrazuril's intended scope and suggest a data-tagging mismatch in the underlying procurement records. The opportunities do reflect broad pharmaceutical and medical-supply procurement across issuing bodies including county health departments, state pharmacy commissions, cities, and multi-state cooperative purchasing alliances, but the specific products and services being solicited bear no direct relationship to the code's pharmaceutical designation.

Recent activity spanning Florida, Texas, and Minnesota includes Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, response deadline July 26, 2023), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs posted April 3, 2026, the City of Tampa's sheltered-market IFB for medical and first aid supplies serving the Fire Department Rescue Division with an estimated contract value of $700,000 and response deadline March 13, 2026, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The code shows little relevant recent activity aligned with its toltrazuril definition; the mismatch between the code's nominal scope and the actual procurement opportunities suggests this classification is not reliably capturing state and local demand for this commodity and warrants verification against the correct UNSPSC assignments for pharmaceutical procurement activity.